Roche Advances In HCV Protease Inhibitor Contest
Swiss pharma will move ITMN-191 into Phase II studies, triggering a $15 million milestone to InterMune.
Swiss pharma will move ITMN-191 into Phase II studies, triggering a $15 million milestone to InterMune.